Detection of pancreatic cancer with normal carbohydrate antigen 19-9 using protein chip technology

World Journal of Gastroenterology

Volumn 20, Issue 40, 2014, Pages 14958-14964

  Jin, Xiao Li ^a   Xu, Bin ^a   Wu, Yu Lian ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Carbohydrate antigen 19 9; Diagnosis; Pancreatic cancer; Screening; Surface enhanced laser desorption ionization time of flight mass spectrometry

Indexed keywords

CA 19-9 ANTIGEN; TUMOR PROTEIN;

ADULT; AGED; BENIGN TUMOR; BIOINFORMATICS; BLOOD LEVEL; CANCER DIAGNOSIS; CANCER PATIENT; CANCER SCREENING; CLINICAL FEATURE; CONTROLLED STUDY; CYSTADENOMA; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; INSULINOMA; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; MALE; PANCREAS CANCER; PREDICTIVE VALUE; PROTEIN EXPRESSION; PROTEIN MICROARRAY; REVIEW; SENSITIVITY AND SPECIFICITY; SERUM; SOLID PSEUDOPAPILLARY TUMOR; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; BIOLOGY; BLOOD; CANCER STAGING; CASE CONTROL STUDY; CLASSIFICATION; DIFFERENTIAL DIAGNOSIS; MASS SPECTROMETRY; MIDDLE AGED; PANCREAS TUMOR; PATHOLOGY; REPRODUCIBILITY; VALIDATION STUDY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CA-19-9 ANTIGEN; CASE-CONTROL STUDIES; COMPUTATIONAL BIOLOGY; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROTEIN ARRAY ANALYSIS; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84910616691     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i40.14958     Document Type: Review

References (22)

1. Duffy MJ, Sturgeon C, Lamerz R, Haglund C, Holubec VL, Klapdor R, Nicolini A, Topolcan O, Heinemann V. Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann Oncol 2010; 21: 441-447 [PMID: 19690057 DOI: 10.1093/annonc/mdp332]
2. Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol 2012; 3: 105-119 [PMID: 22811878 DOI: 10.3978/j.issn.2078-6891.2011.021]
3. Zubarik R, Gordon SR, Lidofsky SD, Anderson SR, Pipas JM, Badger G, Ganguly E, Vecchio J. Screening for pancreatic cancer in a high-risk population with serum CA 19-9 and targeted EUS: a feasibility study. Gastrointest Endosc 2011; 74: 87-95 [PMID: 21704809 DOI: 10.1016/j.gie.2011.03.1235]
4. Joergensen MT, Brünner N, De Muckadell OB. Comparison of circulating MMP-9, TIMP-1 and CA19-9 in the detection of pancreatic cancer. Anticancer Res 2010; 30: 587-592 [PMID: 20332475]
5. Sandblom G, Granroth S, Rasmussen IC. TPS, CA 19-9, VEGF-A, and CEA as diagnostic and prognostic factors in patients with mass lesions in the pancreatic head. Ups J Med Sci 2008; 113: 57-64 [PMID: 18521799 DOI: 10.3109/2000-1967-214]
6. Morris-Stiff G, Taylor MA. Ca19-9 and pancreatic cancer: Is it really that good? J Gastrointest Oncol 2012; 3: 88-89 [PMID: 22811875 DOI: 10.3978/j.issn.2078-6891.2012.016]
7. Ballehaninna UK, Chamberlain RS. Serum CA 19-9 as a Biomarker for Pancreatic Cancer-A Comprehensive Review. Indian J Surg Oncol 2011; 2 : 88-100 [PMID: 22693400 DOI: 10.1007/s13193-011-0042-1]
8. Kim JE, Lee KT, Lee JK, Paik SW, Rhee JC, Choi KW. Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol 2004; 19: 182-186 [PMID: 14731128 DOI: 10.1111/j.1440-1746.2004.03219.x]
9. Wright GL. SELDI proteinchip MS: a platform for biomarker discovery and cancer diagnosis. Expert Rev Mol Diagn 2002; 2: 549-563 [PMID: 12465452 DOI: 10.1586/14737159.2.6.549]
10. Weinberger SR, Boschetti E, Santambien P, Brenac V. Surface-enhanced laser desorption-ionization retentate chromatography mass spectrometry (SELDI-RC-MS): a new method for rapid development of process chromatography conditions. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 782: 307-316 [PMID: 12458014]
11. Yang S, Nan Y, Tian Y, Zhang W, Zhou B, Bu L, Huo S, Chen G, Yu J, Zheng S. Study of distinct protein profiles for early diagnosis of NSCLC using LCM and SELDI-TOF-MS. Med Oncol 2008; 25: 380-386 [PMID: 18300004 DOI: 10.1007/s12032-008-9050-6]
12. Xu WH, Chen YD, Hu Y, Yu JK, Wu XG, Jiang TJ, Zheng S, Zhang SZ. Preoperatively molecular staging with CM10 ProteinChip and SELDI-TOF-MS for colorectal cancer patients. J Zhejiang Univ Sci B 2006; 7: 235-240 [PMID: 16502512 DOI: 10.1631/jzus.2006.B0235]
13. Yu JK, Zheng S, Tang Y, Li L. An integrated approach utilizing proteomics and bioinformatics to detect ovarian cancer. J Zhejiang Univ Sci B 2005; 6: 227-231 [PMID: 15754417 DOI: 10.1631/jzus.2005.B0227]
14. Kim HJ, Kim MH, Myung SJ, Lim BC, Park ET, Yoo KS, Seo DW, Lee SK, Min YI. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve. Am J Gastroenterol 1999; 94: 1941-1946 [PMID: 10406263]
15. Singh S, Tang SJ, Sreenarasimhaiah J, Lara LF, Siddiqui A. The clinical utility and limitations of serum carbohydrate antigen (CA19-9) as a diagnostic tool for pancreatic cancer and cholangiocarcinoma. Dig Dis Sci 2011; 56: 2491-2496 [PMID: 21516323 DOI: 10.1007/s10620-011-1709-8]
16. Molina V, Visa L, Conill C, Navarro S, Escudero JM, Auge JM, Filella X, Lopez-Boado MA, Ferrer J, Fernandez-Cruz L, Molina R. CA 19-9 in pancreatic cancer: retrospective evaluation of patients with suspicion of pancreatic cancer. Tumour Biol 2012; 33: 799-807 [PMID: 22203495 DOI: 10.1007/s13277-011-0297-8]
17. Liao Q, Zhao YP, Yang YC, Li LJ, Long X, Han SM. Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head. Hepatobiliary Pancreat Dis Int 2007; 6: 641-645 [PMID: 18086633]
18. Chen YD, Zheng S, Yu JK, Hu X. Artificial neural networks analysis of surface-enhanced laser desorption/ionization mass spectra of serum protein pattern distinguishes colorectal cancer from healthy population. Clin Cancer Res 2004; 10: 8380-8385 [PMID: 15623616]
19. Wang JX, Zhang B, Yu JK, Liu J, Yang MQ, Zheng S. Application of serum protein fingerprinting coupled with artificial neural network model in diagnosis of hepatocellular carcinoma. Chin Med J (Engl) 2005; 118: 1278-1284 [PMID: 16117882]
20. Duraker N, Hot S, Polat Y, Höbek A, Genc¸ler N, Urhan N. CEA, CA 19-9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice. J Surg Oncol 2007; 95 : 142-147 [PMID: 17262731 DOI: 10.1002/jso.20604]
21. Rai AJ, Zhang Z, Rosenzweig J, Shih IeM, Pham T, Fung ET, Sokoll LJ, Chan DW. Proteomic approaches to tumor marker discovery. Arch Pathol Lab Med 2002; 126: 1518-1526 [PMID: 12456215]
22. Koopmann J, Zhang Z, White N, Rosenzweig J, Fedarko N, Jagannath S, Canto MI, Yeo CJ, Chan DW, Goggins M. Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin Cancer Res 2004; 10: 860-868 [PMID: 14871961]